$TFX — AVOID 📊

$TFX — AVOID 📊 Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applic 🎯 Q2 2026 | Rev $1B | EPS $1.93 vs $3.75 🔴 💡 Consensus likely still prices in a quick rebound to prior earnings levels, but the magnitude of the miss suggests deeper operational issues. Our variant view is that recovery will be slower than implied, keeping the stock under pressure. 📉 Reward/Risk: 1.2:1 🏢 Business Quality: 3/10 - Severe earnings miss signals potential demand, execution, or competitive challenges; high revenue multiple suggests over-optimistic growth assumptions. 📊 Valuation: rich — P/E 64x, P/S 182x vs medical device peers typically 15–25x P/E; even on normalized $3.75 EPS, fwd P/E is 33x, leaving no margin for error. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/TFX0623

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applic